Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 250-257

  Damaj, M I ^a   Siu, E C K ^b   Sellers, E M ^b   Tyndale, R F ^b   Martin, B R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; CYTOCHROME P450 2A5; CYTOCHROME P450 2A6; METHOXSALEN; MORPHINE; NICOTINE; SODIUM CHLORIDE;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; COTININE; ENZYME INHIBITORS; MALE; METHOXSALEN; MICE; MICE, INBRED ICR; MICROSOMES; MIXED FUNCTION OXYGENASES; NICOTINE; OXIDATION-REDUCTION;

EID: 33845898524     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111237     Document Type: Article

References (32)

1. Aceto MD, Martin BR, Uwaydah IM, May EL, Harris LS, Izazola-Conde C, Dewey WL, and Vincek WC (1979) Optically pure (+)-nicotine from (±)-nicotine and biological comparisons with (-)-nicotine. J Med Chem 22:174-177.
2. Ariyoshi N, Sekine H, Saito K, and Kamataki T (2002) Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics 12:501-504.
3. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, and Valverde O (2002) Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43:857-867.
4. Damaj MI and Martin BR (1993) Is the dopaminergic system involved in the central effects of nicotine in mice? Psychopharmacology 111:106-108.
5. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
6. Dewey WL, Harris LS, Howes JS, and Nuite JA (1970) The effect of various neurohormonal modulations on the activity of morphine and the narcotic antagonists in tail-flick and phenylquinone test. J Pharmacol Exp Ther 175:435-442.
7. Draper AJ, Madan A, and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61.
8. Freeman GB, Sherman KA, and Gibson GE (1987) Locomotor activity as a predictor of times and dosages for studies of nicotine's neurochemical actions. Pharmacol Biochem Behav 26:305-312.
9. Gaddnas H, Pietila K, Alila-Johansson A, and Ahtee L (2002) Pineal melatonin and brain transmitter monoamines in CBA mice during chronic oral nicotine administration. Brain Res 957:76-83.
10. Hwa Jung B, Chul Chung B, Chung SJ, and Shim CK (2001) Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. J Control Release 77:183-190.
11. Itzhak Y and Martin JL (1999) Effects of cocaine, nicotine, dizocipline and alcohol on mice locomotor activity: cocaine-alcohol cross-sensitization involves upregulation of striatal dopamine transporter binding sites. Brain Res 818:204-211.
12. Kharasch ED, Hankins DC, and Taraday JK (2000) Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. Drug Metab Dispos 28:28-33.
13. Kita T, Okamoto M, and Nakashima T (1992) Nicotine-induced sensitisation to ambulatory stimulant effect produced by daily administration into the ventral tegmental area and the nucleus accumbens in rats. Life Sci 50:583-590.
14. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
15. Lindberg RL, Juvonen R, and Negishi M (1992) Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh. Pharmacogenetics 2:32-37.
16. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, and Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400-409.
17. Marks MJ, Burch JB, and Collins AC (1983) Genetics of nicotine response in four inbred strains of mice. J Pharmacol Exp Ther 226:291-302.
18. Messina ES, Tyndale RF, and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614.
19. Minematsu N, Nakamura H, Furuuchi M, Nakajima T, Takahashi S, Tateno H, and Ishizaka A (2006) Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur Respir J 27:289-292.
20. Murphy SE, Raulinaitis V, and Brown KM (2005) Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 33:1166-1173.
21. Nakayama H, Okuda H, Nakashima T, Imaoka S, and Funae Y (1993) Nicotine metabolism by rat hepatic cytochrome P450s. Biochem Pharmacol 45:2554-2556.
22. Petersen DR, Norris KJ, and Thompson JA (1984) A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab Dispos 12:725-731.
23. Picciotto MR (2003) Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 24:493-499.
24. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, and Tyndale RF (2000) Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58:747-755.
25. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, and Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615-626.
26. Schoedel KA, Sellers EM, and Tyndale RF (2001) Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem Pharmacol 62:1025-1036.
27. Sellers EM, Kaplan HL, and Tyndale RF (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68:35-43.
28. Siu EC, Wildenauer DB, and Tyndale RF (2006) Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) 184:401-408.
29. Smolen A, Marks MJ, DeFries JC, and Henderson ND (1994) Individual differences in sensitivity to nicotine in mice: response to six generations of selective breeding. Pharmacol Biochem Behav 49:531-540.
30. Tallarida RJ and Murray RB (1987) Manual of Pharmacological Calculations with Computer Programs, Springer-Verlag, New York.
31. Tripathi HL, Martin BR, and Aceto MD (1982) Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J Pharmacol Exp Ther 221:91-96.
32. Zhang W, Kilicarslan T, Tyndale RF, and Sellers EM (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897-902.